2. Search Result
Search Result
Results for "

HT-22

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

6

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D1913
    Fe2Orange
    20+ Cited Publications

    		 Fluorescent Dye Others
    Fe2Orange is a Fe 2+ selective probe with an excitation wavelength of 543 nm and an emission wavelength of 580 nm. Fe2Orange emits fluorescence after binding to intracellular Fe 2+, thereby achieving specific labeling of Fe 2+. Fe2Orange is used to detect the content and distribution of Fe 2+ in cells .
    Fe2Orange
  • HY-14930
    Mirodenafil

    SK3530

    		 Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis Neurological Disease Inflammation/Immunology Endocrinology
    Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
    Mirodenafil
  • HY-B0298
    Clemastine
    10+ Cited Publications

    HS-592; Meclastine

    		 Histamine Receptor mAChR Autophagy Apoptosis Keap1-Nrf2 p62 mTOR Pyroptosis IKK Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Clemastine (HS-592; Meclastine) is an orally active, blood-brain barrier-permeable H1 histamine receptor (H1 histamine receptor) antagonist with potent antiallergic effects. Clemastine also antagonizes muscarinic acetylcholine receptors (mAChR), particularly the M1 and M4 subtypes. In addition to antihistamine effects, Clemastine exhibits multiple pharmacological activities, especially in promoting central nervous system remyelination, activating autophagy and pyroptosis, exerting anti-apoptotic and neuroprotective effects, and suppressing inflammation .
    Clemastine
  • HY-101449
    Adaptaquin
    2 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Inflammation/Immunology
    Adaptaquin is a BBB-penetrable HIF-PHDs inhibitor. Adaptaquin has anti-inflammatory and neuroprotective effects. Adaptaquin can effectively inhibit lipid peroxidation, maintain mitochondrial function, and reduce neuronal death. Adaptaquin can be used in the research of nervous system diseases such as Parkinson's disease .
    Adaptaquin
  • HY-14930A
    Mirodenafil dihydrochloride

    SK-3530 dihydrochloride

    		 Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis Neurological Disease Inflammation/Immunology Endocrinology
    Mirodenafil (SK3530) dihydrochloride is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil dihydrochloride is a glucocorticoid receptor (GR) modulator Mirodenafil dihydrochloride activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil dihydrochloride can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
    Mirodenafil dihydrochloride
  • HY-N1535
    Ponicidin
    4 Publications Verification

    Rubescensine B

    		 Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Cancer
    Ponicidin is an apoptosis inducer, cell growth inhibitor and neuroprotective agent, with a Ka of 135 nM for mouse RIPK1. Ponicidin regulates the JAK2/STAT3 pathway to induce apoptosis, activates the PI3K/Akt pathway, upregulates SIRT1 expression, alleviates oxidative stress, inhibits inflammatory responses and necroptosis, and blocks cell cycle progression. Ponicidin induces ROS production to exert antiproliferative and antiviral effects, while also improving cognitive function and reducing Aβ plaque deposition. Ponicidin is applicable to research related to hepatocellular carcinoma, Alzheimer's disease and gastric cancer .
    Ponicidin
  • HY-135981
    CMS-121
    2 Publications Verification

    		 Acetyl-CoA Carboxylase Neurological Disease Inflammation/Immunology
    CMS-121 is a quinolone derivative and an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC50 values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, anti-inflammatory, antioxidative and renoprotective activities .
    CMS-121
  • HY-139196
    ThioLox

    		Lipoxygenase Neurological Disease Inflammation/Immunology
    ThioLox is a competitive 15-lipoxygenase-1 (15-LOX-1) inhibitor with a Ki of 3.30 μM. ThioLox shows anti-inflammatory and neuroprotective properties .
    ThioLox
  • HY-120553
    B-355252
    1 Publications Verification

    		 Apoptosis Neurological Disease
    B355252, a phenoxy thiophene sulfonamide small molecule, is a potent NGF receptor agonist. B355252 potentiates NGF-induced neurite outgrowth. B355252 protects ischemic neurons from neuronal loss by attenuating DNA damage, reducing ROS production and the LDH level, and preventing neuronal apoptosis. B355252 has anti-apoptotic effects in glutamate-induced excitotoxicity, as well as in a murine hippocampal cell line (HT22) model of Parkinson disease (PD) .
    B-355252
  • HY-153383
    PDCD4-IN-1
    2 Publications Verification

    		 Programmed Cell Death 4 (PDCD4) Cancer
    PDCD4-IN-1(compound 20031600) is a PDCD4 inhibitor with a Kd value of 350 nM, which can promote the expression of BDNF in hippocampal neuron cell HT-22 .
    PDCD4-IN-1
  • HY-136674
    Aftin-5

    		Amyloid-β Neurological Disease
    Aftin-5 is an inducer for Amyloid-β 42 (Aβ42). Aftin-5 upregulates Aβ42 and downregulates Aβ38 levels in a β-secretase- and γ-secretase-dependent manner by altering the ultrastructure of mitochondria. Aftin-5 exhibits slightly cytotoxicity in cell SH-SY5Y, HT22, N2a and N2a-AβPP695, with IC50s of 180, 194, 178 and 150 μM, respectively .
    Aftin-5
  • HY-163280
    JGB-1-155

    		NAMPT Neurological Disease
    JGB-1-155 is a positive allosteric modulators (N-PAMs), which enhances the activity of nicotinamide phosphoribosyltransferase NAMPT with EC50 of 3.29 μM. JGB-1-155 counteracts the oxidative stress, through upregulating the NAD + in THP-1 human monocytes. JGB-1-155 attenuates TNFα-induced ROS in HT-22 cells .
    JGB-1-155
  • HY-W002438
    6-Hydroxyindole

    		Biochemical Assay Reagents Endogenous Metabolite OAT Ferroptosis Neurological Disease Metabolic Disease
    6-Hydroxyindole is an orally active, endogenous long-acting OATP1B1 inhibitor. 6-Hydroxyindole does not alter the cell surface expression or subcellular localization of OATP1B1. 6-Hydroxyindole protects cells against Ferroptosis. 6-Hydroxyindole possesses intrinsic radical-trapping antioxidant activity. 6-Hydroxyindole serves as a component of oxidative hair dyes. 6-Hydroxyindole can be used in research related to renal failure and neurodegenerative diseases .
    6-Hydroxyindole
  • HY-100218B
    (1R,3S)-RSL3

    		Glutathione Peroxidase Ferroptosis Cancer
    (1R,3S)-RSL3 is the less active (1R,3S)-enantiomer of RSL3 ((1S,3R)-RSL3). (1R,3S)-RSL3 and RSL3 induce cell death in HT22 wild-type cells with EC50 values of 5.2 µM and 0.004 µM, rspectively .
    (1R,3S)-RSL3
  • HY-149764
    Aβ42 agonist-2

    		Amyloid-β Neurological Disease
    Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
    Aβ42 agonist-2
  • HY-N9966
    Sanggenol O

    		Others Others
    Sanggenol O? is an active product that can be extracted from Morus alba. Sanggenol O? has hepatoprotective and neuroprotective activities with EC50s more than 80 μM in HepG2 and HT22 cells .
    Sanggenol O
  • HY-175675
    P2Y1 antagonist 4

    		P2Y Receptor Keap1-Nrf2 Cardiovascular Disease Neurological Disease
    P2Y1 antagonist 4 is a selective P2Y1 receptor antagonist with excellent blood-brain barrier (BBB) penetration. P2Y1 antagonist 4 inhibits P2Y1 receptor-mediated cytosolic Ca 2+ increase (IC50 = 1.95 μM) and platelet aggregation (IC50 = 3.24 μM) induced by ADP in rabbit washed platelets. P2Y1 antagonist 4 significantly upregulates the level of nuclear Nrf2 protein in H2O2-treated HT22 cells. P2Y1 antagonist 4 reduces myocardial infarct size in a mouse acute myocardial infarction (MI) model. P2Y1 antagonist 4 can be used for the study of ischemic stroke and myocardial infarction .
    P2Y1 antagonist 4
  • HY-139382
    2-(Isopentylamino)naphthalene-1,4-dione

    		Cytochrome P450 Neurological Disease
    2-(Isopentylamino)naphthalene-1,4-dione (compound 3d), a Vitamin K (HY-B2172) analogue, shows protection in Pentylenetetrazole (PTZ)-induced seizure model. 2-(Isopentylamino)naphthalene-1,4-dione significantly increases ATP levels in zebrafish as well as HT-22 cells. 2-(Isopentylamino)naphthalene-1,4-dione shows excellent permeability into the brain .
    2-(Isopentylamino)naphthalene-1,4-dione
  • HY-170367
    Antimicrobial agent-35

    		Bacterial Infection
    Antimicrobial agent-35 (Compound c9) exhibits antibacterial agent, that inhibits S. aureus, E. coli, E. faecalis, and S. maltophilia with MIC of 0.5-2 μg/mL. Antimicrobial agent-35 exhibits cytotoxicity against HT-22 with IC50 of 130.4 μg/mL .
    Antimicrobial agent-35
  • HY-14930R
    Mirodenafil (Standard)

    SK3530 (Standard)

    		 Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis Reference Standards Neurological Disease Inflammation/Immunology Endocrinology
    Mirodenafil (Standard) is the analytical standard of Mirodenafil. This product is intended for research and analytical applications. Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
    Mirodenafil (Standard)
  • HY-161327
    HBV-IN-44

    		HBV Infection
    HBV-IN-44 (Compound (S)-2a) is a HBV inhibitor with a IC50 value of 23 nM for HbsAg. HBV-IN-44 is less toxic to the neurite growth of HT22 cells and DRG neurons in vitro .
    HBV-IN-44
  • HY-N8464
    Juncuenin D

    		Bacterial Cancer
    Juncuenin D induces caspase-3-mediated cytotoxicity in HT22 cells. Juncuenin D also has anti-bacterial activity against MRSA strains. Juncuenin D can be isolated from J. effusus .
    Juncuenin D
  • HY-N8412
    4-O-Methylbutein

    		Others Neurological Disease
    4-O-Methylbutein is a phenolic glucoside that can be isolated from Elsholtzia ciliata.4-O-Methylbutein exhibits neuroprotective effects against glutamate-induced HT22 cell death with an EC50 of 35.2 μM .
    4-O-Methylbutein
  • HY-149763
    Aβ42 agonist-1

    		Amyloid-β Neurological Disease
    Aβ42 agonist-1 is a compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
    Aβ42 agonist-1
  • HY-W670700
    2,5-Dihydroxy-4-methoxyacetophenone

    		MMP Others
    2,5-Dihydroxy-4-methoxyacetophenone (compounds 3) can be isolated from the 80% methanol extract of roots of Cynanchum paniculatum Kitagawa. 2,5-Dihydroxy-4-methoxyacetophenone inhibits glutamate-induced cytotoxicity in hippocampal HT22 cell line . 2,5-Dihydroxy-4-methoxyacetophenone significantly inhibites MMP-13 expression in SW1353 cells, and have the potential for alleviating cartilage degradation .
    2,5-Dihydroxy-4-methoxyacetophenone
  • HY-178352
    MAO-B-IN-49

    		Monoamine Oxidase Reactive Oxygen Species (ROS) Neurological Disease Inflammation/Immunology
    MAO-B-IN-49 is a selective and reversible MAO-B inhibitor (IC50 of 1 nM for human MAO-B). MAO-B-IN-49 shows much higher selectivity for MAO-B than for MAO-A (IC50 = 633.9 μM). MAO-B-IN-49 can reduce ROS production induced by Lipopolysaccharides (HY-D1056) (LPS) in HT22 cells. MAO-B-IN-49 demonstrates substantial neuroprotective properties and significantly improves motor dysfunction in MPTP (HY-W114750)-induced mouse models of Parkinson’s disease (PD). MAO-B-IN-49 can be used for the study of PD .
    MAO-B-IN-49
  • HY-172599
    GSK-3β probe-1

    		GSK-3 Neurological Disease
    GSK-3β probe-1 (10c) is a GSK-3β probe (Ex = 341 nm, Em= 574nm, ɛ= 3.51 × 10 4L/mol·cm −1) and can be be used in the study of Alzheimer's disease .
    GSK-3β probe-1
  • HY-151386
    BChE-IN-13

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-13 (Compound 17c) is an orally active, potent and selective Butyrylcholinesterase (BChE) inhibitor with IC50s of 0.22 and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 can improve memory and cognitive impairments, and be used in Alzheimer’s disease (AD) research .
    BChE-IN-13
  • HY-14930AR
    Mirodenafil dihydrochloride (Standard)

    SK-3530 dihydrochloride (Standard)

    		 Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis Reference Standards Neurological Disease Inflammation/Immunology Endocrinology
    Mirodenafil (dihydrochloride) (Standard) is the analytical standard of Mirodenafil (dihydrochloride). This product is intended for research and analytical applications. Mirodenafil (SK3530) dihydrochloride is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil dihydrochloride is a glucocorticoid receptor (GR) modulator Mirodenafil dihydrochloride activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil dihydrochloride can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
    Mirodenafil dihydrochloride (Standard)
  • HY-180806
    RIPK1-IN-39

    		RIP kinase Apoptosis Cardiovascular Disease Neurological Disease
    RIPK1-IN-39 (compound 2) is a potent and selective RIPK1 inhibitor (IC50 = 69.40 nM) exhibiting >100-fold selectivity over RIPK3 (IC50 = 6946 nM). RIPK1-IN-39 protects HT-22 and HT-29 cells from necroptosis by inhibiting the phosphorylation and activation of the RIPK1-RIPK3-MLKL pathway. RIPK1-IN-39 demonstrates neuroprotective effects in a rat model of middle cerebral artery occlusion (MCAO). RIPK1-IN-39 can be used for acute ischemic stroke (AIS) research .
    RIPK1-IN-39
  • HY-180327
    NEPP11

    		Drug Derivative Apoptosis Keap1-Nrf2 Raf MEK ERK Neurological Disease Inflammation/Immunology
    NEPP11 is a cyclopentenone prostaglandin analogue. NEPP11 can inhibit glutamate-induced HT22 cell death in mouse hippocampus and prevent manganese-induced apoptosis in PC12 cells. NEPP11 can activate Nrf2 and maintain MEK1/2 and ERK1/2 activity by inhibiting c-Raf downregulation. NEPP11 exerts a neuroprotective effect in a mouse model of focal cerebral ischemia caused by permanent middle cerebral artery occlusion .
    NEPP11
  • HY-402805
    DYRK2-IN-2

    		DYRK CDK Tau Protein Cancer
    DYRK2-IN-2 (Compound C17) is a selective inhibitor of DYRK2, with its IC50 value being 40.3 nM. The inhibitory activity of DYRK2-IN-2 on DYRK1A (IC50 = 1842 nM), DYRK1B (IC50 = 1335 nM), DYRK4 (IC50 = 1931 nM), DYRK3 (IC50 = 112 nM), and CLKs (IC50 = 540-6496 NM) is relatively low. DYRK2-IN-2 inhibits the phosphorylation of Tau protein at Thr212 and shows moderate cytotoxicity in HT22 cells. DYRK2-IN-2 can be used in cancer research .
    DYRK2-IN-2
  • HY-180197
    PICK1 PDZ-IN-1

    		PKC iGluR Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease
    PICK1 PDZ-IN-1 (Compound 6b) is a selective and brain-penetrant protein interacting with C kinase 1 (PICK1) PDZ domain inhibitor with a Ki of 27.73 μM. PICK1 PDZ-IN-1 can competitively inhibit the interaction between PICK1 and the GluA2 subunit of AMPA receptors. PICK1 PDZ-IN-1 can increase the survival rate of HT22 cells and primary cortical neuron cells induced by glutamate and inhibit ROS production. PICK1 PDZ-IN-1 exhibits neuroprotective effect and reduces the area of cerebral infarction. PICK1 PDZ-IN-1 can be used for the research of ischemic stroke .
    PICK1 PDZ-IN-1
  • HY-101449R
    Adaptaquin (Standard)

    		HIF/HIF Prolyl-Hydroxylase Reference Standards Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Inflammation/Immunology
    Adaptaquin (Standard) is the analytical standard of Adaptaquin (HY-101449). This product is intended for research and analytical applications. Adaptaquin is a BBB-penetrable HIF-PHDs inhibitor. Adaptaquin has anti-inflammatory and neuroprotective effects. Adaptaquin can effectively inhibit lipid peroxidation, maintain mitochondrial function, and reduce neuronal death. Adaptaquin can be used in the research of nervous system diseases such as Parkinson's disease .
    Adaptaquin (Standard)
  • HY-181665
    Ferroptosis-IN-23

    		Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) Apoptosis Neurological Disease
    Ferroptosis-IN-23 is an inhibitor of ferroptosis. Ferroptosis-IN-23 exerts a synergistic effect by simultaneously activating Steap4 and glutathione peroxidase 4 (GPX4), thereby maintaining iron metabolism homeostasis. Ferroptosis-IN-23 reverses neuronal ferroptosis and inhibits lipid ROS accumulation in cells. Ferroptosis-IN-23 inhibits ferroptosis in zebrafish, alleviates neuronal apoptosis, ROS accumulation, and dopaminergic neuron damage in a zebrafish model of Parkinson's disease. Ferroptosis-IN-23 can be used for research on Parkinson's disease .
    Ferroptosis-IN-23
  • HY-178141
    AChE/BuChE-IN-7

    		Cholinesterase (ChE) Neurological Disease
    AChE/BuChE-IN-7 is a dual-action inhibitor with an IC50 valueof 0.15 μM for AChE and 0.7 μM for BuChE, SI of 4.7. AChE/BuChE-IN-7 shows anti-oxidant activity and can mitigate H2O2-induced cytotoxicity. AChE/BuChE-IN-7 has genomic stability and prolonged systemic availability. AChE/BuChE-IN-7 can be used for the research of neurological disease, such as Alzheimer's disease .
    AChE/BuChE-IN-7
  • HY-175823
    1,4-Naphthoquinone-NH-C2-NH-Trolox

    		Ferroptosis Reactive Oxygen Species (ROS) Neurological Disease
    1,4-Naphthoquinone-NH-C2-NH-Trolox is a brain-penetrant Trolox (HY-101445)-vitamin K (HY-B2172) conjugate with neuroprotective activity. 1,4-Naphthoquinone-NH-C2-NH-Trolox can inhibit oxytosis, ferroptosis, ATP depletion and ROS production. 1,4-Naphthoquinone-NH-C2-NH-Trolox selective suppresses M1 markers expression. 1,4-Naphthoquinone-NH-C2-NH-Trolox can be used for the research of neurological disease, such as Alzheimer’s disease (AD) .
    1,4-Naphthoquinone-NH-C2-NH-Trolox
  • HY-183660
    F-SLOH

    		Autophagy Amyloid-β Tau Protein Neurological Disease
    F-SLOH is a brain-penerant and orally active TFEB activator and amyloid-β inhibitor with an IC50 of 3.4 μM against amyloid-β. F-SLOH promotes nuclear translocation of TFEB, driving autophagy and lysosomal biogenesis. F-SLOH reduces amyloid-β oligomers and Tau aggregates via autophagy lysosomal degradation pathway. F-SLOH can be used for the research of Alzheimer’s disease .
    F-SLOH
  • HY-181549
    PDE4-IN-32

    		Phosphodiesterase (PDE) Cardiovascular Disease Neurological Disease
    PDE4-IN-32 (Compound B05) is a selective, blood-brain barrier permeable PDE4B and PDE4D inhibitor with IC50 values of 13.7 nM and 23.8 nM, respectively. PDE4-IN-32 promotes the recovery of motor and cognitive function in MCAO/R mouse models. PDE4-IN-32 reduces cerebral edema. PDE4-IN-32 can be used for the research of ischemic stroke .
    PDE4-IN-32
  • HY-183805
    5-HT6R/FAAH modulator 2

    		5-HT Receptor FAAH Neurological Disease
    5-HT6R/FAAH modulator 2 is a dual 5-HT6R antagonist and FAAH inhibitor with human 5-HT6R pKi 7.24, human FAAH pIC50 5.47, and blood-brain barrier penetration.5-HT6R/FAAH modulator 2 modulates serotonergic signaling, blocks 5-HT6R function, inhibits endocannabinoid degradation via FAAH catalytic activity suppression.5-HT6R/FAAH modulator 2 exhibits neuroprotective effects against mitochondrial dysfunction, amyloid-β, and glutamate-induced toxicity, reverses memory deficits.5-HT6R/FAAH modulator 2 shows reduced cytotoxicity relative to oxygen-containing lead compounds.5-HT6R/FAAH modulator 2 can be used for the research of Alzheimer's disease .
    5-HT6R/FAAH modulator 2
  • HY-181178
    (Mor-Cor)Ag(III)

    		Amyloid-β Neurological Disease
    (Mor-Cor)Ag(III) is a blood-brain barrier-penetrant silver(III) corrole complex that penetrates the blood-brain barrier. (Mor-Cor)Ag(III) scavenges reactive oxygen species induced by Aβ42 and disrupts Aβ42 aggregation, attenuating Aβ42-induced neuronal hyperactivity. (Mor-Cor)Ag(III) can be used for the research of Alzheimer's disease .
    (Mor-Cor)Ag(III)
  • HY-183944
    BN80933

    		NO Synthase Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease
    BN80933 is a selective neuronal nitric oxide synthase (nNOS) inhibitor with a rat Ki of 0.92 μM. BN80933 inhibits lipid peroxidation, and blocks hypoxia-induced lactate dehydrogenase elevation and delayed 8-epiprostaglandin F2α elevation. BN80933 can be used for the research of stroke, and traumatic brain injury .
    BN80933

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: